Opioid Crisis Litigation Intensifies: OptumRx and Express Scripts Appeal Judge’s Ruling Allowing New Lawsuits

Amid ongoing legal battles surrounding the opioid crisis, pharmacy benefit managers OptumRx and Express Scripts have petitioned the U.S. Court of Appeals for the Sixth Circuit. Their appeal seeks to reverse U.S. District Judge Dan Polster’s July 27 order, which opened the doors for 800 plaintiffs to sue them. The case highlights the increasingly complex litigation landscape facing companies involved in the distribution and administration of opioid medications.

These pharmacy benefit managers have played a pivotal role in the prescription drug supply chain, managing pharmacy benefits for health plans and serving as intermediaries between drug manufacturers, pharmacies, and insurers. The current appeal is a part of the broader multidistrict litigation that consolidates thousands of lawsuits across various U.S. jurisdictions against manufacturers, distributors, and retailers of opioid medications. A report by Law.com provides detailed coverage of this development.

Judge Polster’s decision has been controversial, as it allows local governments and other entities grappling with the opioid epidemic to hold these intermediaries accountable. This is part of a larger effort to address the devastating impact of opioid addiction on communities nationwide. The defendants argue that the lawsuits unfairly target them for the actions of manufacturers and prescribers.

Legal experts are closely watching how the Sixth Circuit will respond to this appeal. The case could set significant precedents for how liability is distributed among different parties in the pharmaceutical supply chain. This development follows a series of settlements and verdicts against other companies within the industry, as public outcry and legal pressure mount.

As this legal saga unfolds, implications for corporate strategy in managing legal risks associated with healthcare operations become increasingly pertinent. Stakeholders across the healthcare spectrum remain vigilant, anticipating further legal challenges and potential shifts in industry practices that may arise from this case.